Chelsea Azevedo
Internal Medicine · Long Beach, CANPI 1881274900
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,453 of the $1,707 with a category attached, or 85.1%. It is spread thinly across 25 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,278, more than ten times the $124 reported in 2023.
Across 49 payments — averaging $34.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$223
- AstraZeneca$172
- Bristol Myers Squibb$146
- Paratek Pharmaceuticals, Inc.$125
- Genentech USA, Inc.$113
- Johnson & Johnson$101
- plus $827 from 19 others
What the payments were for
- Food & beverage$1,45385%
- Education$25415%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $223 |
| AstraZeneca(2 entities) | 4 | $172 |
| Bristol Myers Squibb | 7 | $146 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Genentech USA, Inc. | 4 | $113 |
| Johnson & Johnson | 3 | $101 |
| Seagen Inc. | 1 | $100 |
| Lilly USA, LLC | 2 | $93 |
| AbbVie | 3 | $74 |
| Jazz Pharmaceuticals Inc. | 2 | $71 |
| Springworks Therapeutics, Inc. | 2 | $60 |
| Incyte Corporation | 2 | $54 |
| ADC Therapeutics America, Inc. | 1 | $33 |
| Pfizer | 1 | $32 |
| Menarini Silicon Biosystems, Inc. | 1 | $32 |
| Syndax Pharmaceuticals, Inc. | 1 | $32 |
| Gilead | 1 | $31 |
| Sanofi | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Deciphera Pharmaceuticals Inc. | 1 | $29 |
| Beigene USA, Inc. | 1 | $29 |
| Array Biopharma Inc | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,707 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 18 | $290 |
| Amlodipine Besylate | 15 | $140 |
| Lisinopril | 20 | $96 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Long Beach
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.